Alexion Pharmaceuticals, Inc.
EFFICACY OF AN ANTI-C5 ANTIBODY IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION IN SENSITIZED RECIPIENTS OF KIDNEY TRANSPLANT

Abstract:

A method for preventing AMR in a human kidney transplant recipient is provided. The method comprises: selecting a deceased donor; selecting a kidney transplant recipient; transplanting the kidney from the donor to the recipient; and administering a therapeutically effective dose of an anti-C5 antibody or fragment thereof to the recipient. The recipient is generally sensitized to the donor. Also provided is a method for treating AMR in a kidney transplant patient. The method comprises: selecting a kidney transplant patient having symptoms of AMR; and administering a therapeutically effective dose of an anti-C5 antibody or fragment thereof to the patient; wherein the dose of the anti-C5 antibody or fragment thereof reduces the symptoms of AMR.